Zobrazeno 1 - 10
of 99
pro vyhledávání: '"her2-low breast cancer"'
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Backgrounds To develop a machine learning (ML) model for predicting the prognosis of breast cancer (BC) patients with low human epidermal growth factor receptor 2 (HER2) expression, and to investigate the association between clinicopathologi
Externí odkaz:
https://doaj.org/article/738e5608a81a438a9eec5ec92ad8352d
Publikováno v:
Breast Cancer: Targets and Therapy, Vol Volume 16, Pp 667-678 (2024)
Man Huang,1,2,* Yudi Jin,3,* Mengyuan Wang,2 Qiang Song,4 Yanjia Fan,1 Yu Zhang,1 Cheng Tian,1 Chi Zhang,1 Shengchun Liu1 1Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, Peo
Externí odkaz:
https://doaj.org/article/8d83ddca3ce04f8994588dd14d24ddb9
Autor:
Ko HC, Seager RJ, Pabla S, Senosain MF, Van Roey E, Gao S, Strickland KC, Previs RA, Green MF, Cooper M, Nesline MK, Hastings SB, Amoah KA, Zhang S, Conroy JM, Jensen TJ, Eisenberg M, Caveney B, Severson EA, Ramkissoon S, Gandhi S
Publikováno v:
Breast Cancer: Targets and Therapy, Vol Volume 16, Pp 483-495 (2024)
Heidi Chwan Ko,1,* RJ Seager,2,* Sarabjot Pabla,2 Maria-Fernanda Senosain,2 Erik Van Roey,2 Shuang Gao,2 Kyle C Strickland,1,3 Rebecca Ann Previs,1,4 Michelle F Green,1 Maureen Cooper,1 Mary K Nesline,1 Stephanie B Hastings,1 Kobina Agyaful A
Externí odkaz:
https://doaj.org/article/d724bcda24c84b0ab1bf160d027c478b
Autor:
Hanna Bartkowiak, Damian Grubski, Kacper Ziarnik, Filip Nadolny, Jędrzej Jabłoński, Martyna Kania, Agnieszka Adamowska, Alicja Śniatała
Publikováno v:
Journal of Education, Health and Sport, Vol 75 (2024)
Introduction: Breast cancer is one of the most commonly diagnosed malignant tumors among women worldwide. HER2 receptor is a protein that plays a role in cell growth, division, and repair. Approximately 50% of HER2 –negative breast cancers express
Externí odkaz:
https://doaj.org/article/4ccbd4a0bc7c41b58ad693350815163e
Autor:
Yingying Zhao, Xinru Chen, Yaohui Wang, Xueqing Zhang, Yumei Ye, Shuguang Xu, Liheng Zhou, Yanping Lin, Jingsong Lu, Wenjin Yin
Publikováno v:
Annals of Medicine, Vol 56, Iss 1 (2024)
Background Temporal heterogeneity in human epidermal growth factor receptor 2 (HER2) status may be associated with the prognosis of breast cancer. We aimed to clarify the relationship of HER2-low transition during neoadjuvant therapy with survival ou
Externí odkaz:
https://doaj.org/article/9fbe93b15a5d4324a4fcfbc251583360
Autor:
Michael Sode, Kåre Nielsen, Maj-Britt Jensen, Tobias Berg, Ann Knoop, Bent Ejlertsen, Anne-Vibeke Lænkholm
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background and purpose: We investigated the prognosis of breast cancer (BC) with low expression of human epidermal growth factor receptor 2 (HER2), as previous studies have found varying impacts on survival of HER2-low BC compared with HER2 0 BC (HER
Externí odkaz:
https://doaj.org/article/23de7ff8c85c46a18a7018b883ff9989
Autor:
Juan Jin, Bin Li, Jianing Cao, Ting Li, Jian Zhang, Jun Cao, Mingchuan Zhao, Leiping Wang, Biyun Wang, Zhonghua Tao, Xichun Hu
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-16 (2023)
Abstract Background Novel human epidermal growth factor receptor 2 (HER2)-directed antibody–drug conjugates prompt the identification of the HER2-low subtype. However, the biological significance of HER2-low expression in breast cancer is unclear.
Externí odkaz:
https://doaj.org/article/feeb8b6d8ae14d6982b8b819747c5496
Publikováno v:
Breast Cancer: Targets and Therapy, Vol Volume 15, Pp 281-294 (2023)
Jin Wang,1– 3,* Dongying Liao,1– 3,* Xuemin Zhang,1– 3 Changhong Miao,1– 3 Kuang Chen1– 3 1Department of Emergency, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, People’s Republic
Externí odkaz:
https://doaj.org/article/90ba8d3a47cd4887822fbc8005841dc8
Publikováno v:
Breast, Vol 67, Iss , Pp 1-7 (2023)
Novel anti-HER2 antibody-drug conjugates trastuzumab deruxtecan (DS-8201a) showed its effect in previously-treated HER2-low metastatic breast cancer, suggesting a promising future in HER2-low breast cancer. We retrospectively reviewed the clinicopath
Externí odkaz:
https://doaj.org/article/3106b4fc4b3a4ab7addaf132f290d2e1
Publikováno v:
Breast Cancer: Targets and Therapy, Vol Volume 14, Pp 453-463 (2022)
Yitian Lang,1 Bin Wu,2 Xiaoyan Liu1 1Department of Pharmacy, Huangpu Branch, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 2Medical Decision and Economic Group, Departmen
Externí odkaz:
https://doaj.org/article/17ca4d596e3e400ea9344aa1103d55f3